Tamoxifen inhibits TGF-β/Smad pathway and reduces pathological proliferation of human dermal fibroblasts

doi:10.16352/j.issn.1001-6325.2022.09.1367

Abstract

Abstract: Objective To explore the function and mechanism of tamoxifen, an estrogen receptor modulator, in the pathogenesis of hyperplatic scar. Methods Primary human fibroblasts were isolated and cultured for 4 generations and then aliquated into 3 groups: control group, TGF-β1 group and TGF-β1+ tamoxifen group. The effects of tamoxifen on human fibrogenic factor production, cell proliferation, migration and differentiation of TGF-β1-induced skin fibroblasts were detected by real-time quantitative polymerase chain reaction (RT-qPCR), MTS, cell scratch test, Western blot and immunofluorescence assay. Results Tamoxifen (10 μmol/L) inhibited the production of collagen 1, collagen 3 and α-SMA induced by TGF-β1 in fibroblasts. MTS results showed that the proliferation activity of TGF-β1 group was higher than that of tamoxifen group (P＜0.05). Wound healing test verified that the migration ability of cells was reduced by tamoxifen intervention. Tamoxifen inhibited collagen secretion and differentiation of skin fibroblasts into muscle fibroblasts. Conclusions The estrogen receptor modulator tamoxifen inhibits pathological proliferation of fibroblasts, so it may be a potential novel strategy for the treatment of hyperplastic scar.

Key words: hyperplastic scar, tamoxifen, TGF-β, skin fibroblasts

CLC Number:

SHI Chun-tian, MAO Shu-ran, PENG Yi-xuan, XIAO Zhi-bo. Tamoxifen inhibits TGF-β/Smad pathway and reduces pathological proliferation of human dermal fibroblasts[J]. Basic & Clinical Medicine, 2022, 42(9): 1367-1373.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.09.1367

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I9/1367

References 20

[1]	Chen L, Wang J, Li S,et al. The clinical dynamic changes of macrophage phenotype and function in different stages of human wound healing and hypertrophic scar formation[J]. Int Wound J,2019,16:360-369.
[2]	Finnerty CC, Jeschke MG, Branski LK,et al. Hypertro-phic scarring: the greatest unmet challenge after burn injury[J]. Lancet,2016,388:1427-1436.
[3]	Elhai M, Avouac J, Walker UA, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study[J]. Ann Rheum Dis,2016,75:163-169.
[4]	Lockshin MD. Sex differences in autoimmune disease[J]. Lupus,2006,15:753-756.
[5]	Ruzehaji N, Avouac J, Elhai M, et al. Combined effect of genetic background and gender in a mouse model of bleomycin-induced skin fibrosis[J]. Arthritis Res Ther, 2015,17:145.doi:10.1186/s13075-015-0659-5.
[6]	Aida-Yasuoka K, Peoples C, Yasuoka H, et al. Estradiol promotes the development of a fibrotic phenotype and is increased in the serum of patients with systemic sclerosis[J]. Arthritis Res Ther,2013,15:R10. doi:10.1186/ar4140.
[7]	Soldano S, Montagna P, Brizzolara R, et al. Effects of estrogens on extracellular matrix synthesis in cultures of human normal and scleroderma skin fibroblasts[J]. Ann N Y Acad Sci, 2010,1193:25-29.
[8]	Bock O, Schmid-Ott G, Malewski P, et al. Quality of life of patients with keloid and hypertrophic scarring[J]. Arch Dermatol Res, 2006,297:433-438.
[9]	Hinz B, Phan SH, Thannickal VJ, et al.The myofibroblast: one function, multiple origins[J]. Am J Pathol,2007,170:1807-1816.
[10]	Desmoulière A, Geinoz A, Gabbiani F, et al. Transform-ing growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts[J]. J Cell Biol,1993,122:103-111.
[11]	Kim D, Lee AS, Jung YJ,et al. Tamoxifen ameliorates renal tubulointerstitial fibrosis by modulation of estrogen receptor α-mediated transforming growth factor-β1/Smad signaling pathway[J]. Nephrol Dial Transplant, 2014,29:2043-2053.
[12]	Yoldas O, Karaca T, Bilgin BC,et al. Tamoxifen citrate: a glimmer of hope for silicosis[J]. J Surg Res,2015,193:429-434.
[13]	Dellê H, Rocha JR, Cavaglieri RC,et al. Antifibrotic effect of tamoxifen in a model of progressive renal disease[J]. J Am Soc Nephrol,2012,23:37-48.
[14]	van Bommel EF, Hendriksz TR, Huiskes AW,et al. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis[J]. Ann Intern Med,2006,144:101-106.
[15]	Mousavi SR, Raaiszadeh M, Aminseresht M,et al. Evaluating tamoxifen effect in the prevention of hypertrophic scars following surgical incisions[J]. Dermatol Surg,2010,36:665-669.
[16]	Mikulec AA, Hanasono MM, Lum J,et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts[J]. Arch Facial Plast Surg,2001,3:111-114.
[17]	Otranto M, Sarrazy V, Bonté F,et al. The role of the myofibroblast in tumor stroma remodeling[J]. Cell Adh Migr,2012,6:203-219.
[18]	Luga V, Wrana JL. Tumor-stroma interaction: revealing fibroblast-secreted exosomes as potent regulators of Wnt-planar cell polarity signaling in cancer metastasis[J]. Cancer Res,2013,73:6843-6847.
[19]	Shimoda M, Principe S, Jackson HW,et al. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state[J]. Nat Cell Biol,2014,16:889-901.
[20]	Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer[J]. Breast Care (Basel),2014,9:391-396.